Literature DB >> 18824910

Treatment-related risk factors for hospital mortality in Candida bloodstream infections.

Andrew J Labelle1, Scott T Micek, Nareg Roubinian, Marin H Kollef.   

Abstract

OBJECTIVE: To examine the relationship between treatment-related variables for Candida bloodstream infection and hospital mortality.
DESIGN: Retrospective cohort analysis.
SETTING: Thousand two hundred-bed academic medical center. PATIENTS: A total of 245 consecutive patients with Candida bloodstream infections who received antifungal therapy.
INTERVENTIONS: Identification of treatment-related risk factors: central vein catheter retention, inadequate initial fluconazole dosing, and delayed administration of antifungal therapy.
MEASUREMENTS AND MAIN RESULTS: A total of 245 patients with Candida bloodstream infections who received antifungal therapy were identified. One hundred eleven (45.3%) patients were managed in an intensive care unit and analyzed as a separate subgroup. In the hospital cohort, 72 (29.4%) patients died during hospitalization and 40 (36.0%) patients died in the intensive care unit cohort. In the hospital cohort, logistic regression analysis identified Acute Physiology and Chronic Health Evaluation II scores (1-point increments) (adjusted odds ratio [AOR], 1.18; 95% confidence interval [CI], 1.11-1.25; p = 0.003), corticosteroid use at the time a positive blood culture was drawn (AOR, 3.41; 95% CI, 1.96-5.93; p = 0.027), inadequate initial fluconazole dosing (AOR, 3.31; 95% CI, 1.83-6.00; p = 0.044), and retention of a central vein catheter (AOR, 4.85; 95% CI, 2.54-9.29; p = 0.015) as independent determinants of hospital mortality. In the intensive care unit cohort, logistic regression analysis identified Acute Physiology and Chronic Health Evaluation II scores (1-point increments) (AOR, 1.21; 95% CI, 1.14-1.29; p = 0.001), inadequate initial fluconazole dosing (AOR, 9.22; 95% CI, 2.15-19.79; p = 0.004), and retention of a central vein catheter (AOR, 6.21; 95% CI, 3.02-12.77; p = 0.011), as independent determinants of hospital mortality. For both cohorts the incremental presence of treatment-related risk factors was statistically associated with greater hospital mortality.
CONCLUSIONS: Treatment-related factors, including retention of central vein catheters and inadequate initial fluconazole dosing, were associated with increased hospital mortality in patients with Candida bloodstream infections. These data suggest that optimization of initial antifungal therapy and removal of central vein catheters may improve the outcomes of patients with Candida bloodstream infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18824910     DOI: 10.1097/CCM.0b013e31818b3477

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  59 in total

1.  The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Authors:  Themistoklis K Kourkoumpetis; George C Velmahos; Panayiotis D Ziakas; Emmanouil Tampakakis; Dimitra Manolakaki; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2010-10-08       Impact factor: 2.574

Review 2.  Advances in the management of sepsis and the understanding of key immunologic defects.

Authors:  Lee P Skrupky; Paul W Kerby; Richard S Hotchkiss
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

3.  Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels.

Authors:  S Kurland; M Furebring; E Löwdin; E Eliasson; E I Nielsen; J Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring.

Authors:  Indy Sandaradura; Jessica Wojciechowski; Deborah J E Marriott; Richard O Day; Sophie Stocker; Stephanie E Reuter
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

5.  Update on invasive opportunistic mycoses: clinical trials review, 2008-2009.

Authors:  Andreas H Groll
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

Review 6.  Clinical aspects of invasive candidiasis in critically ill patients.

Authors:  Mariano Pennisi; Massimo Antonelli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

8.  Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study.

Authors:  Marya D Zilberberg; Marin H Kollef; Heather Arnold; Andrew Labelle; Scott T Micek; Smita Kothari; Andrew F Shorr
Journal:  BMC Infect Dis       Date:  2010-06-03       Impact factor: 3.090

9.  Candidemia on presentation to the hospital: development and validation of a risk score.

Authors:  Andrew F Shorr; Ying P Tabak; Richard S Johannes; Xiaowu Sun; James Spalding; Marin H Kollef
Journal:  Crit Care       Date:  2009-09-29       Impact factor: 9.097

10.  Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.

Authors:  Marya D Zilberberg; Smita Kothari; Andrew F Shorr
Journal:  Crit Care       Date:  2009-06-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.